en · de · es · fr · pt
sr9009-notes.peptides6155.com › Data › Background And Pharmacological Mechanism — Field Notes

Background And Pharmacological Mechanism — Field Notes

By Editorial Desk · published 2025-07-18 · last reviewed 2025-08-21 · Data

Everything below concerns circadian clock. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2025-08-21. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Pharmacological Mechanism

SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.

SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.

Analytical and Handling Considerations

For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.

Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.

Sr9009 at a glance

PropertyValueNotes
Molecular formulaC20H24ClN3O4SReported for the free base
Molecular weight437.9 g/molCalculated from the formula
Primary targetREV-ERBα and REV-ERBβNuclear receptors involved in circadian regulation
SolubilitySoluble in DMSO and ethanolPoorly soluble in water
Typical storage-20 °C, desiccatedProtect from light and moisture

Detection, Regulation, and Misconceptions

Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.

Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.

Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.

Related pages on this site

Handling Storage and Quality Control

Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.

Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.

Background and Mechanism

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.

At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.

Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.

Background and Mechanism of SR9009

Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.

SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.

Reference notes

Since at least 2013, scientists have been trying to develop synthetic third-generation vaccines by reconstructing the outside structure of a virus; it was hoped that this would help prevent vaccine resistance. Principles that govern the immune response can now be used in tailor-made vaccines against many noninfectious human diseases, such as cancers and autoimmune disorders. For example, the experimental vaccine CYT006-AngQb has been investigated as a possible treatment for high blood pressure. Factors that affect the trends of vaccine development include progress in translatory medicine, demographics, regulatory science, political, cultural, and social responses.

The secretome is the set of proteins expressed by an organism and secreted into the extracellular space. In humans, this subset of the proteome encompasses 13-20% of all proteins, including cytokines, growth factors, extracellular matrix proteins and regulators, and shed receptors. The secretome of a specific tissue can be measured by mass spectrometry and its analysis constitutes a type of proteomics known as secretomics.

On November 16, 2004, Valve released Half-Life 2. The game had a six-year development cycle, which saw several delays and the leak of the game's source code in October, 2003. Half-Life 2 returns the player to the role of Gordon Freeman. Set twenty years after the original game, Earth has been occupied by the Combine, a transdimensional race that exploited the events of the first game to invade. The G-Man inserts Freeman into City 17 in Eastern Europe to combat the Combine occupation. Considered one of the greatest video games of all time, Half-Life 2 was praised for its advances in computer animation, sound, narration, computer graphics, artificial intelligence and physics, and won more than 35 Game of the Year awards. Half-Life 2 was the first game to use Valve's Steam content delivery system, a system that eventually led to Valve falling out with publisher Sierra Entertainment.

Taken by mouth, valproate is rapidly and virtually completely absorbed from the gut. When in the bloodstream, 80–90% of the substance are bound to plasma proteins, mainly albumin. Protein binding is saturable: it decreases with increasing valproate concentration, low albumin concentrations, the patient's age, additional use of other drugs such as aspirin, as well as liver and kidney impairment. Concentrations in the cerebrospinal fluid and in breast milk are 1 to 10% of blood plasma concentrations. The vast majority of valproate metabolism occurs in the liver. Valproate is known to be metabolized by the cytochrome P450 enzymes CYP2A6, CYP2B6, CYP2C9, and CYP3A5. It is also known to be metabolized by the UDP-glucuronosyltransferase enzymes UGT1A3, UGT1A4, UGT1A6, UGT1A8, UGT1A9, UGT1A10, UGT2B7, and UGT2B15. Some of the known metabolites of valproate by these enzymes and uncharacterized enzymes include (see image):

==== Initial outbreak ==== In December 2019, an outbreak of coronavirus disease 2019 (COVID-19) was first identified in Wuhan, Hubei, China; it spread worldwide and was recognized as a pandemic by the World Health Organization (WHO) on March 11, 2020. The first confirmed case in Canada was in Ontario—reported on January 27, 2020. On March 17, Ford declared a state of emergency in Ontario, closing bars and restaurants (with the exception of take-out and delivery services), as well as libraries, theatres, cinemas, schools and daycares and all public gatherings of more than 50 people (later reduced to 5 people on March 28). Furthermore, the government announced on March 17 that Ontario had "some evidence of community transmission" of COVID-19. On March 23, Ford announced that all "non-essential" businesses would be ordered closed starting 11:59 p.m. On March 24. Ford also stated that schools would remain closed past the original April 6 opening date (on May 19 it was announced that schools would remain closed until the following school year in September). A list of 74 "essential" businesses was published later in the day on March 23. On March 25, Ford and Finance Minister Rod Phillips introduced a $17-billion response package that includes an influx of cash for the health sector, direct payments to parents and tax breaks for businesses.

Sources: en.wikipedia.org

Reference notes

== Timeline == After filing for bankruptcy, ownership of the hospital went up for bid, and there were two major corporations interested: Adventist Health with University of California San Francisco (UCSF) and American Advanced Management. During this time, a loan of 57 million dollars was approved for the reopening of the hospital from a state funded 300 million dollar bailout program for struggling hospitals in California. Ultimately, the bankruptcy court approved the bid from American Advanced Management in mid February 2024. The hospital has since been moving forward with rebuilding and upgrading, and CEO Steve Stark has goals to reopen by February 2025, given that they are able to fill the necessary positions.

A further way of carrying out glycosylation is by using enzymes, known as chemo-enzymatic glycosylation. This method is used for complex chemical synthesis. Chemical and chemo-enzymatic methods can be used for the synthesis of glycopeptides and glycoproteins. Cyclization can also be used as a method to decrease proteolytic degradation and prolong half-life, to make the peptide conformation more rigid to hinder enzymatic cleavage. This method can however lead to loss of biological function due to the reduced flexibility making the peptide inactive. For example, side chain to side chain cyclization between asparagine (position 8) and lysine (position 12), of a growth regulating factor (GRF) analogue was found to increase the half-life from 17 minutes to more than 2 hours. Another way to extend half-life do is to bind serum albumin to the peptide. Human serum albumin is the most abundant plasma protein with a molecular weight of 66.4 kDa, and it is involved in many essential bodily functions to maintain homoeostasis. As a result, albumin binding would significantly increase the molecular weight of the peptide, restricting it from being filtered into the urine by the GBM. Serum albumin has an extraordinary long half-life of 2–4 weeks which is much longer than other plasma proteins, due to it binding to the neonatal Fc receptor (FcRn). Fc receptors are proteins found on the surface of certain cells that help to protect the functions of the immune system, by binding to the Fc region of antibodies, which attach to pathogens and destroy them.

Along with mirtazapine, although to a lesser extent in comparison, mianserin has sometimes been described as a noradrenergic and specific serotonergic antidepressant (NaSSA). However, the actual evidence in support of this label has been regarded as poor.

=== Brain surgeries === In February 1988, after several episodes of severe neck pain, Biden underwent surgery to correct a leaking intracranial berry aneurysm. While recuperating, he suffered a pulmonary embolism. A second aneurysm was surgically repaired in May. His recuperation kept him away from the Senate for seven months.

Sources: en.wikipedia.org

Reference notes

=== Hearing loss === Hearing loss in Treacher Collins syndrome is caused by deformed structures in the outer and middle ear. The hearing loss is generally bilateral with a conductive loss of about 50–70 dB. Even in cases with normal auricles and open external auditory canals, the ossicular chain is often malformed. Attempts to surgically reconstruct the external auditory canal and improve hearing in children with TCS have not yielded positive results. Auditory rehabilitation with bone-anchored hearing aids (BAHAs) or a conventional bone conduction aid has proven preferable to surgical reconstruction.

The U.S. Department of Energy (DOE) has published a list of yearly technical system targets for on-board hydrogen storage for light-duty fuel cell vehicles which guide researchers in the field (5.5 wt %/40 g L−1 by 2017; 7.5 wt %/70 g L−1 ultimate). Materials with high porosity and high surface area such as MOFs have been designed and synthesized in an effort to meet these targets. These adsorptive materials generally work via physical adsorption rather than chemisorption due to the large HOMO–LUMO gap and low HOMO energy level of molecular hydrogen. A benchmark material to this end is MOF-177 which was found to store hydrogen at 7.5 wt % with a volumetric capacity of 32 g L−1 at 77 K and 70 bar. MOF-177 consists of [Zn4O]6+ clusters interconnected by 1,3,5-benzenetribenzoate organic linkers and has a measured BET surface area of 4630 m2 g−1. Another exemplary material is PCN-61 which exhibits a hydrogen uptake of 6.24 wt % and 42.5 g L−1 at 35 bar and 77 K and 2.25 wt % at atmospheric pressure. PCN-61 consists of [Cu2]4+ paddle-wheel units connected through 5,5′,5′′-benzene-1,3,5-triyltris(1-ethynyl-2-isophthalate) organic linkers and has a measured BET surface area of 3000 m2 g−1. Despite these promising MOF examples, the classes of synthetic porous materials with the highest performance for practical hydrogen storage are activated carbon and covalent organic frameworks (COFs).

In plants and most microorganisms, tyrosine is produced via prephenate, an intermediate on the shikimate pathway. Prephenate is oxidatively decarboxylated with retention of the hydroxyl group to give p-hydroxyphenylpyruvate, which is transaminated using glutamate as the nitrogen source to give tyrosine and α-ketoglutarate. Mammals synthesize tyrosine from the essential amino acid phenylalanine (Phe), which is derived from food. The conversion of Phe to Tyr is catalyzed by the enzyme phenylalanine hydroxylase, a monooxygenase. This enzyme catalyzes the reaction causing the addition of a hydroxyl group to the end of the 6-carbon aromatic ring of phenylalanine, such that it becomes tyrosine.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.

How does it work?

It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.

Is it proven to increase endurance in humans?

No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.

How is SR9009 detected in laboratory samples?

Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.

Network